Subcutaneous Epcoritamab Shows Promise in Some Non-Hodgkin Lymphoma Patients
NEW YORK (Reuters Health) – Single-agent subcutaneous epcoritamab appears to benefit patients ...
Combo Provides ‘Broad Benefit’ Across NHL Subtypes
The combination of copanlisib plus rituximab led t...
